Day One Biopharmaceuticals, Inc. (DAWN)

16.17 +0.14 (+0.87%) 收市：04:00PM EDT

Day One Biopharmaceuticals, Inc.

2000 Sierra Point Parkway
Suite 501
Brisbane, CA 94005
United States
650 484 0899
https://dayonebio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 174

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Jeremy Bender M.B.A., Ph.D.	CEO, President & Director	1.05M	無	1971
Dr. Samuel C. Blackman M.D., Ph.D.	Co-Founder and Head of R&D	740.5k	無	1969
Mr. Charles N. York II, M.B.A.	COO, CFO & Secretary	760k	無	1977
Mr. Adam Dubow	General Counsel and Chief Compliance Officer	608.2k	無	1967
Dr. Mike Preigh Ph.D.	Chief of Technology Operations	無	無	無
Ms. Jaa Roberson	Chief People Officer	無	無	無
Dr. Davy Chiodin Ph.D., Pharm.D.	Chief Development Officer	無	無	無
Ms. Lauren Merendino M.B.A.	Chief Commercial Officer	無	無	1976
Dr. Elly Barry M.D.	Chief Medical Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

公司管治

截至 2024年5月1日 止，Day One Biopharmaceuticals, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：6；董事會：5；股東權利：8；現金賠償：8。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。